The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19

The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19

Mostrar otras versiones (1)

Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptom...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rafael Venegas Rodríguez, Anabel Serrano Díaz, Rubén Peña Ruiz, Raúl Santana Sánchez, Aliusha Rittoles Navarro, Inti Grecesqui Cruz, Liam Manuel Pérez Aguilera, Anadys Segura Fernández, Mabel Hernández-Cedeño, Leticia Rosario Cruz, Deyli Chacón Montano, Gillian Martínez-Donato, Gerardo Guillén-Nieto, María del Carmen Domínguez Horta
Formato: article
Lenguaje:ES
Publicado: ECIMED 2021
Materias:
covid-19
hiperinflamación
hipercoagulación hsp60
cigb-258
jusvinza.
Medicine
R
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/1bbf749ca5744f84841c0b91c9011f33
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/1bbf749ca5744f84841c0b91c9011f33

Ejemplares similares